ReviewMedicina (Kaunas, Lithuania)2022

Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer.

Faisal K Alkholifi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.